


| | CLAIMS REMAINING AFTER AMENDMENT | | HIGHEST NUMBER PREVIOUSLY PAID FOR | | PRESENT EXTRA | RATE | ADDITIONAL FEE |
|---|---|---|---|---|------------------|-------|-------------------|
| TOTAL | 9 | - | 20 | = | 0 | \$ 18 | \$0.00 |
| INDEPENDENT | 3 | - | 3 | = | 0 | \$ 84 | \$0.00 |
| <input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM | | | | | | \$280 | \$0.00 |
| | | | | | | TOTAL | \$0.00 |

- ☒ Petition for one (1) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$110.00 for the extension of time.
- ☐ No fee is required.
- ☒ Check(s) in the amount of \$110.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181

pn
MSW/PW/jeb
2016-0165P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000



#7

BOX AF
REPLY UNDER
37 C.F.R. § 1.116
EXPEDITED PROCEDURE
PATENT
2016-1655
MAY 16 2002
TECHNICAL CENTER 1600/2900

RECEIVED

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: KIMURA et al. Conf.: 4810
Appl. No.: 09/678,330 Group: 1624
Filed: October 3, 2000 Examiner: BALASUBRAMANIAN, V.
For: DIAMINOSTILBENE DERIVATIVES

*Ambr
R & R
5-28-02*

REPLY AFTER FINAL UNDER 37 C.F.R. § 1.116

BOX AF

Assistant Commissioner for Patents
Washington, DC 20231

May 13, 2002
(Monday)

Sir:

In reply to the Final Office Action dated January 11, 2002, the period for response having been extended until May 13, 2002, the following remarks are respectfully submitted in connection with the above-identified application.

REMARKS

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 1-9 will remain pending in the above-identified application and stand ready for further action on the merits.